Angiotensin II blockade before and after marked sodium depletion in patients with hypertension
- PMID: 620496
- DOI: 10.1042/cs0540075
Angiotensin II blockade before and after marked sodium depletion in patients with hypertension
Abstract
1. Angiotensin II blockade before and after marked sodium depletion in patients with hypertension [unilateral renovascular (eight), bilateral renovascular (four) and essential (four)] was performed by intravenous administration of the angiotensin II antagonist Sar1-Ala8-angiotensin II (saralasin). 2. On normal sodium intake, saralasin decreased mean blood pressure by 8 mmHg in the unilateral renovascular group, by 6 mmHg in the bilateral renovascular group and increased it by 3 mmHg in the essential hypertensive group. After sodium depletion saralasin decreased mean blood pressure by 33 mmHg, 35 mmHg and 18 mmHg respectively. The saralasin-induced decrease in blood pressure significantly correlated with the log of the initial plasma renin activity. 3. Saralasin infusion decreased effective renal plasma flow (ERPF) in all three hypertension subgroups, both on normal sodium intake and after sodium depletion. Glomerular filtration rate decreased in direct relation to the hypotensive effect of saralasin but ERPF showed this relationship only after sodium depletion. On normal sodium intake saralasin increased filtration fraction by 17%, but decreased it by 7% after sodium depletion. 4. It is concluded that the hypotensive action of saralasin closely correlates with the value of circulating plasma renin activity, apparently independent of the aetiology of the hypertension. The decrease in ERPF during saralasin infusion in the patients on normal sodium intake seems mainly related to the agonistic activity of saralasin, but that after sodium depletion to the hypotensive effect of saralasin.
Similar articles
-
The influence of sar1 ala8 angiotensin II (saralasin) on plasma aldosterone in hypertensive patients.Acta Med Scand. 1979;205(3):207-12. doi: 10.1111/j.0954-6820.1979.tb06032.x. Acta Med Scand. 1979. PMID: 425848 Clinical Trial.
-
Effects of the angiotensin II antagonist 1-sar-8-ala-angiotensin II in hypertension in man.Eur J Clin Invest. 1977 Dec;7(6):473-9. doi: 10.1111/j.1365-2362.1977.tb01638.x. Eur J Clin Invest. 1977. PMID: 415868
-
Haemodynamic effects of Sar1-Ala8-angiotensin II in patients with renovascular hypertension.Prog Biochem Pharmacol. 1976;12:242-9. Prog Biochem Pharmacol. 1976. PMID: 1019167
-
Angiotensin II blockade and the functions of the renin-angiotensin system.Prog Biochem Pharmacol. 1976;12:1-15. Prog Biochem Pharmacol. 1976. PMID: 798202 Review.
-
Pathophysiology of diastolic hypertension.Health Psychol. 1988;7 Suppl:15-31. doi: 10.1037/h0090269. Health Psychol. 1988. PMID: 3072177 Review.
Cited by
-
Possible significance of the pharmacological differentiation of beta-blockers for therapy of hypertension.Br J Clin Pharmacol. 1979;7 Suppl 2(Suppl 2):173S-184S. doi: 10.1111/j.1365-2125.1979.tb04688.x. Br J Clin Pharmacol. 1979. PMID: 37872 Free PMC article.
-
Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.Drugs. 2001;61(7):943-54. doi: 10.2165/00003495-200161070-00004. Drugs. 2001. PMID: 11434450 Review.
-
Patients with uncontrolled hypertension or concomitant hypertension and benign prostatic hyperplasia.Clin Cardiol. 2004 Feb;27(2):63-9. doi: 10.1002/clc.4960270203. Clin Cardiol. 2004. PMID: 14979621 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources